Iktos announced research alliance with Almirall for new drug design
By Nikita Chaurasia  Date: 2019-12-14

Iktos announced research alliance with Almirall for new drug design
  • The new drug design to involve AI technology for optimization of advanced compounds and boosting up the identification if drug candidates for Almirall drug discovery program.
  • The agreement is likely to provide rapid identification of molecules for the satisfaction of multiple bioactivity for clinical trials.
  • Under the pact, Almirall would leverage Iktos’s AI accuracy to bring about a difference in the patients’ lives.

One of the prominent AI companies dealing in novel drug design, Iktos, has reportedly announced establishing a research partnership with leading skin-health focused pharmaceutical company, Almirall on the grounds of designing novel drug compounds via the use of Iktos’ AI technology.

As per reliable reports, Iktos’ AI technology offers high speed and efficiency to the drug discovery process through automatically designing virtual molecules that display desirable characteristics of an advanced drug candidate. This is apprehended to tacked one of the fundamental challenges in drug design which is the rapid and repetitive identification of molecules that authenticate the multiple bioactive attributes for testing.

On this acquisition, the executive Vice president R&D and Chief Scientific Officer of Almirall, Dr. Bhushan Hardas was quoted stating that the collaboration serves as an example of how the company intends to explore myriad possibilities served by the technology to discover new molecules and boost the clinical development. He further added that the company has planned to stand at the forefront of innovations to build holistic and transversal approaches in the medical field. AI is anticipated to offer Almirall a distinctive opportunity to amalgamate its skills with an intent to augmenting patients’ lives.

Meanwhile, the president and CEO of Iktos, Yann Gaston- Mathe, cited that the company is delighted to be partnered with Almirall as this collaboration would bolster the leadership position of the company in the domain of AI for new drug design. 

Iktos has of late announced umpteen collaborations and mergers with the biopharmaceutical companies where the company lays immense focus on accelerating the design of promising compounds.

Source credit: https://finance.yahoo.com/news/iktos-almirall-announce-research-collaboration-080100761.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...

Algae cultivator Qualitas Health raises USD 10 million in funding round
Algae cultivator Qualitas Health raises USD 10 million in funding round
By Nikita Chaurasia

In recent developments, privately held food and nutrition company Qualitas Health Inc. has reportedly secured USD 10 million in venture funds, as it looks to broaden the reach of its plant-based protein and omega-3 business. The company was appraised...

China touts plans of launching national ETS to attain carbon neutrality
China touts plans of launching national ETS to attain carbon neutrality
By Nikita Chaurasia

According to reliable sources, the Chinese government is expected to launch the much anticipated national emission trade scheme (ETS) by mid-2021 as a part of the country’s efforts of achieving carbon-neutrality by the year 2060, through market...

Fujifilm to develop large-scale cell culture manufacturing site in U.S.
Fujifilm to develop large-scale cell culture manufacturing site in U.S.
By Nikita Chaurasia

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufact...

EMQ expands operations in South Korea to strengthen payment capabilities
EMQ expands operations in South Korea to strengthen payment capabilities
By Nikita Chaurasia

Hong Kong-based multinational financial settlement network EMQ Inc. has reportedly expanded its operations into South Korea to increase access to its global network ecosystem and offer more transparent as well as efficient cross-border payout capabil...